Log in or Sign up for Free to view tailored content for your specialty!
Schizophrenia News
People with schizophrenia included in biobanks may be less severely affected
Volunteer-based biobanks can provide insight into people with less severe forms of illnesses like schizophrenia compared with samples recruited from clinical settings, according to a study published in JAMA Psychiatry.
Adults with strabismus up to 3 times more likely to have mental health conditions
Adults with strabismus were more likely to have mental health conditions, including anxiety, depression and substance use and addiction, compared with those without strabismus, according to a study published in JAMA Ophthalmology.
Log in or Sign up for Free to view tailored content for your specialty!
Psychiatric diagnosis not associated with worse outcomes after fracture-related infection
According to results published in Orthopedics, patients with vs. without psychiatric diagnoses, such as depression, bipolar disorder, anxiety disorder and schizophrenia, had similar clinical outcomes after fracture-related infection.
Neurosterix launches with $63 million to advance allosteric modulator therapeutics
A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.
Bristol Myers acquires Karuna, including novel muscarinic neuropsychiatric drug
Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.
Repetitive transcranial magnetic stimulation alleviates psychomotor slowing from psychosis
Three weeks of 1-Hz repetitive transcranial magnetic stimulation effectively alleviated psychomotor slowing among people with schizophrenia spectrum disorder, according to a study published in JAMA Psychiatry.
Data show ‘robust’ relationship between schizophrenia, heart disease in women
Epidemiological data show women with schizophrenia are 63% more likely to develop CVD during 3.5 years of follow-up compared with those without the condition, with a greater risk observed for women with obesity.
FDA rejects new drug application for schizophrenia treatment
The FDA has declined to approve a new drug application for roluperidone to treat negative symptoms in individuals with schizophrenia.
Quolet completes phase 1 study of oral, lipid-based CBD in healthy volunteers
Quolet Industries has announced the completion of a phase 1 study evaluating a novel, lipid formulation of pure CBD as a potential treatment for various psychiatric and neurologic conditions.
Long-acting injectable antipsychotics lower hospital readmission rates for schizophrenia
Long-acting injectable antipsychotic medications reduced hospital readmission rates among patients with schizophrenia and schizoaffective disorder compared with oral antipsychotic medications, according to a recent study.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read